ABSCI CORP (ABSI)
Health Care · NASDAQ
AI-native clinical-stage biopharmaceutical company using generative design to discover antibody therapeutics for underexplored targets at capital-efficient speeds.
What ABSCI CORP does
Absci is a clinical-stage biopharmaceutical company using an AI-native drug discovery platform called the Integrated Drug Creation platform to design antibody therapeutics targeting underexplored biological mechanisms. The platform combines Origin-1, a generative AI design model, with rapid lab-based validation (lab-in-the-loop) to develop drug candidates in approximately 2 years at ~$15 million per program—significantly faster and cheaper than industry averages. The company is advancing ABS-201, an anti-prolactin receptor (PRLR) antibody with an extended half-life, through Phase 1/2a clinical trials for androgenetic alopecia (AGA) and toward Phase 2 development for endometriosis.
Themes: ["AI drug discovery","Generative AI therapeutics design","Antibody therapeutics","Androgenetic alopecia (AGA / hair loss)","Endometriosis treatment","First-in-class / disease-modifying antibodies","Capital-efficient drug development"]
Fundamentals
- Price$11.47 as of 2026-07-09 close
- Market cap$1.9B as of 2026-07-10
- 1-year return+320.5% as of 2026-07-09 close
- Net margin-6450.8% as of 2026-07-10
- ROE-63.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-61.9% as of 2026-07-10
- Revenue CAGR (3y)-1.8% SEC XBRL
- Beta2.39 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Genentech / Roche (antibody therapeutics)
- Regeneron Pharmaceuticals (antibody platform)
- Amgen (antibody therapeutics)
- Moderna (AI-guided therapeutics)
- DeepMind (AI drug discovery)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.